X4 Pharmaceuticals (XFOR) Receivables - Other (2018 - 2025)
X4 Pharmaceuticals (XFOR) has disclosed Receivables - Other for 8 consecutive years, with $715000.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Receivables - Other fell 33.36% year-over-year to $715000.0, compared with a TTM value of $715000.0 through Sep 2025, down 33.36%, and an annual FY2024 reading of $640000.0, up 13.88% over the prior year.
- Receivables - Other was $715000.0 for Q3 2025 at X4 Pharmaceuticals, down from $720000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $1.2 million in Q4 2022 and bottomed at $393000.0 in Q3 2023.
- Average Receivables - Other over 5 years is $778315.8, with a median of $747000.0 recorded in 2021.
- The sharpest move saw Receivables - Other plummeted 56.77% in 2023, then soared 173.03% in 2024.
- Year by year, Receivables - Other stood at $747000.0 in 2021, then skyrocketed by 54.22% to $1.2 million in 2022, then crashed by 51.22% to $562000.0 in 2023, then increased by 13.88% to $640000.0 in 2024, then increased by 11.72% to $715000.0 in 2025.
- Business Quant data shows Receivables - Other for XFOR at $715000.0 in Q3 2025, $720000.0 in Q2 2025, and $665000.0 in Q1 2025.